Clinical and immunological characteristics of PAH patients and SSc patients assessed for AFA by 2-DE
| Groups of patients | Non-SSc PAH patients | All SSc patients |
| Number of patients (women) | 36 (28) | 24 (20) |
| Age, years (mean, SD) | 38.9 (15.1) | 54.8 (16.6) |
| PAH, n | 36 | 12 |
| Pulmonary fibrosis (n) | 0 | PAH+ 0/12 |
| PAH− 4/12 | ||
| Disease duration, months (mean, SD) | 27.4 (41.4)† | 106.0 (81.1)* |
| 25.3 (19.4)† | ||
| Autoantibodies | ANA (n = 1) | ANA (n = 24) |
| ACA (n = 12) | ||
| Antitopo 1 (n = 3) |
*Disease duration of systemic sclerosis (SSc); †disease duration of pulmonary arterial hypertension (PAH); ACA, anticentromere antibodies; AFA, antifibroblast antibody; ANA, antinuclear antibodies; Antitopo 1, antitopoisomerase 1 antibodies; 2-DE, two-dimensional electrophoresis.